Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Flagship Ventures Expands Stake in Tetraphase Pharmaceuticals Inc (TTPH)

A market-moving update, Flagship Ventures reported ownership of about 2.1 million shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) in a 13D filing with the Securities and Exchange Commission. At the current price of stock, the holding has a value of $16.5 million. Overall, the investor holds a 10.4% stake in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). According to our database, Flagship has previously owned 491,824 shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Flagship Ventures is engaged in investing in early-stage companies.

Generally speaking, 13D filings with the SEC represent the aim of activist investors. These managers are big shots in the investment world and seek to impose their will to an already standing business model.

Empirical studies have demonstrated that retail investors who follow the activity of the funds we track can outbeat the general indices by about 18 percentage points annually. (Learn more details here)

Biopharmaceutical company, Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) is a company engaged in developing antibiotics for different serious infections. Even though, Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) reported a loss in the first quarter of 2013, it is on the good path, narrowing the net loss to $2.8 million, from $4.7 million reported a year earlier. The company succeeded in surging its revenues, which totalled $2.7 million in the three months of 2013, from only $0.5 million in the same period of the last year. Also, in March Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has completed its IPO, which involved 10,714,286 shares of the company, the company said in a statement.

Equally as important, we should mention that the portfolio of Flagship Ventures contains over 30 holdings and consists mainly of private equities.  The fund invests in three sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. From the public companies in the equity portfolio of Flagship Ventures, aside from Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) we can mention: Receptos Inc (NASDAQ:RCPT), BG Medicine, Inc.(NASDAQ:BGMD), and Helicos BioSciences Corp. (OTCMKTS:HLCSQ), according to data on Flagship’s website.

With that in mind we will let you know about the smart money’s plays surrounding Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH).